AIDX 20/20 Biolabs, Inc.
Services-Testing Laboratories · Nasdaq · SEC CIK 1139685 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin29.7%
Operating margin-249.2%
Net margin-317.8%
FCF margin—
EBITDA margin-246.8%
Returns
ROE-1,768.6%
ROA—
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets56.8%
Debt / equity0.00x
Current ratio1.62x
Interest coverage-7.51x
Cash quality & payout
Operating cash flow / net income0.52x
Accruals ratio—
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $2.05M | $1.75M |
| Cost of revenue | $1.44M | $1.39M |
| Gross profit | $604,541 | $360,311 |
| R&D expense | $592,569 | $1.26M |
| SG&A expense | $3.34M | $4.76M |
| Operating income | -$3.33M | -$5.68M |
| Interest expense | $156,207 | $12,646 |
| Net income | -$3.74M | -$5.55M |
| EBITDA | -$3.27M | -$5.56M |
| EPS (basic) | -0.76 | -1.16 |
| EPS (diluted) | -0.76 | -1.16 |
| Weighted avg. shares (diluted) | 4.93M | 4.80M |
| Balance sheet | ||
| Cash & equivalents | $1.03M | $1.78M |
| Receivables | $199,954 | $135,272 |
| Inventory | $116,217 | $47,164 |
| Current assets | $1.47M | $2.03M |
| PP&E, net | $56,677 | $116,669 |
| Intangibles | $202,264 | $205,529 |
| Total assets | $4.14M | $3.58M |
| Current liabilities | $2.46M | $1.36M |
| Total liabilities | $4.16M | $2.08M |
| Shareholders' equity | -$19,225 | $1.51M |
| Shares outstanding | 5.44M | 4.82M |
| Cash flow statement | ||
| Operating cash flow | -$1.92M | -$2.60M |
| Financing cash flow | $1.16M | $293,333 |
| Depreciation & amortization | $63,257 | $116,035 |
| Stock-based compensation | $516,180 | $2.18M |
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.